Advertisement

Preclinical Pharmacology

  • Ronald D. Smith
  • Peter S. Wolf
  • John R. Regan
  • Stanley R. Jolly
Conference paper
Part of the Progress in Clinical Biochemistry and Medicine book series (PCBM, volume 6)

Abstract

The definitional characteristics of CEBs (Sect. 1.3) portray two primary sites of action, the heart and vascular smooth muscle. The acute pharmacologic profile of each CEB reflects actions at both sites. In addition, CEBs can be expected to have other effects related to inhibition of excitation-contraction coupling (e.g. nonvascular smooth muscle) or excitation-secretion coupling. The acute response to CEBs will hemodynamically represent a complex expression of direct (e.g. vasodilator and cardiac) and indirect [e.g. reflex sympathetic activation 565) or inhibition of aldosterone release 566)] effects.

Keywords

Airway Smooth Muscle Thyrotropin Release Hormone Prolactin Secretion Calcium Overload Calcium Accumulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Ronald D. Smith
    • 1
  • Peter S. Wolf
    • 2
  • John R. Regan
    • 3
  • Stanley R. Jolly
    • 4
  1. 1.Department of Pharmaceutical ResearchDu Pont Critical CareWaukeganUSA
  2. 2.Sterling Drug, Inc.New YorkUSA
  3. 3.Rorer Central ResearchFort WashingtonUSA
  4. 4.East Carolina University, School of MedicineGreenvilleUSA

Personalised recommendations